BridgeMD
CATALINA-2: A Phase 2 Study of TORL-1-23 in Advanced Ovarian Cancer
EU CTIS ID: 2024-517190-24-00
What this study is testing
To assess the efficacy of TORL-1-23 as a monotherapy in women with advanced (PROC) expressing CLDN6
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Females aged 18 years or older with confirmed diagnosis of advanced (unresectable) or metastatic high grade serious ovarian, primary peritoneal (ie, of primary origin), or fallopian tube cancer that resistant to platinum-containing therapy.
- Participant’s tumor must show CLDN6 expression, as defined by the CLDN6 reference laboratory assay.
- Have measurable tumor at baseline
- Based on their disease and availability in their region, participants must have received prior treatment with bevacizumab, mirvetuximab soravtansine, and/or a PARP inhibitor.
You likely can't join if
- Participants with clear cell, mucinous, sarcomatous (including carcinosarcoma), mixed histology, or low-grade, borderline ovarian tumors or non-epithelial ovarian cancers
- Participants with primary platinum-refractory ovarian, primary peritoneal (ie, of primary origin) or fallopian tube cancer, defined as disease that did not respond to or has progressed within 3 months of the last dose of first line platinum-containing chemotherapy
- Still experiencing significant adverse events from previous cancer treatments
- Recently received other cancer treatments (within 14 days for most drugs, or 28 days for biologics) before starting this new drug.
- Has received treatment with a CLDN6-targeting agent or an monomethyl auristatin E (MMAE)-containing antibody drug conjugate
The study team makes the final eligibility decision.
Where it's taking place
- Korea, Republic of
- Australia
- Singapore
- Canada
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Korea, Republic of; Australia; Singapore; Canada; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.